Bulletin
Investor Alert

OptimizeRx Corp.

NAS: OPRX

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

May 11, 2021, 4:51 p.m.

/zigman2/quotes/201436739/composite

$

44.56

Change

0.00 0.00%

Volume

Volume 2,974

Quotes are delayed by 20 min

/zigman2/quotes/201436739/composite

Today's close

$ 45.03

$ 44.56

Change

-0.47 -1.04%

Day low

Day high

$41.00

$45.42

Open

52 week low

52 week high

$9.21

$63.98

Open

Company Description

OptimizeRx Corp. engages in the provision of digital health messaging via electronic health records, which serves as a direct channel for pharmaceutical companies to communicate with healthcare providers. It offers EHR workflow solutions which include financial messaging, patient education, and bran...

OptimizeRx Corp. engages in the provision of digital health messaging via electronic health records, which serves as a direct channel for pharmaceutical companies to communicate with healthcare providers. It offers EHR workflow solutions which include financial messaging, patient education, and brand messaging; and brand support. The company was founded by David A. Harrell on November 8, 1985 and is headquartered in Rochester, MI.

Valuation

Price to Sales Ratio

10.67

Price to Book Ratio

9.49

Enterprise Value to Sales

10.43

Total Debt to Enterprise Value

0.00

Efficiency

Revenue/Employee

759,883.00

Income Per Employee

-38,722.00

Receivables Turnover

3.42

Total Asset Turnover

0.74

Liquidity

Current Ratio

3.28

Quick Ratio

3.28

Cash Ratio

1.05

Profitability

Gross Margin

43.54

Operating Margin

-4.93

Pretax Margin

-5.10

Net Margin

-5.10

Return on Assets

-3.77

Return on Equity

-4.65

Return on Total Capital

-4.46

Return on Invested Capital

-4.62

Capital Structure

Total Debt to Total Equity

0.90

Total Debt to Total Capital

0.89

Total Debt to Total Assets

0.74

Long-Term Debt to Equity

0.65

Long-Term Debt to Total Capital

0.65

Officers and Executives

Name Age Officer Since Title
Mr. William J. Febbo 50 2016 Chief Executive Officer & Director
Ms. Miriam J. Paramore 57 2017 President & Chief Strategy Officer
Mr. Douglas Paul Baker 63 2014 Chief Financial Officer
Mr. Todd Inman - 2019 Vice President-Technology
Mr. Angelo Campano - 2020 Senior Vice President & Principal-Agency Channels

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
03/31/2021 Gus D. Halas
Director
539   Award at $0 per share. 0
03/31/2021 Ellen O'Connor Vos
Director
539   Award at $0 per share. 0
03/31/2021 James D. Lang
Director
539   Award at $0 per share. 0
03/31/2021 Patrick D. Spangler
Director
539   Award at $0 per share. 0
03/31/2021 Gregory D. Wasson
Director
539   Award at $0 per share. 0
03/25/2021 William J. Febbo
CHIEF EXECUTIVE OFFICER; Director
26,710   Derivative/Non-derivative trans. at $47.44 per share. 1,267,122
03/25/2021 William J. Febbo
CHIEF EXECUTIVE OFFICER; Director
80,000   Disposition at $46.1 per share. 3,688,000
03/25/2021 William J. Febbo
CHIEF EXECUTIVE OFFICER; Director
394,739   Derivative/Non-derivative trans. at $3.21 per share. 1,267,112
03/24/2021 William J. Febbo
CHIEF EXECUTIVE OFFICER; Director
20,000   Disposition at $50.5 per share. 1,010,000
01/29/2021 Douglas Paul Baker
CHIEF FINANCIAL OFFICER
4,315   Derivative/Non-derivative trans. at $7.51 per share. 32,405
01/29/2021 Douglas Paul Baker
CHIEF FINANCIAL OFFICER
5,032   Disposition at $47.25 per share. 237,762
01/13/2021 Douglas Paul Baker
CHIEF FINANCIAL OFFICER
5,000   Derivative/Non-derivative trans. at $7.51 per share. 37,550
01/13/2021 Douglas Paul Baker
CHIEF FINANCIAL OFFICER
5,000   Disposition at $38.89 per share. 194,450
01/04/2021 Douglas Paul Baker
CHIEF FINANCIAL OFFICER
4,000   Derivative/Non-derivative trans. at $7.51 per share. 30,040
01/04/2021 Douglas Paul Baker
CHIEF FINANCIAL OFFICER
4,566   Derivative/Non-derivative trans. at $2.46 per share. 11,232
01/04/2021 Douglas Paul Baker
CHIEF FINANCIAL OFFICER
8,334   Disposition at $32.88 per share. 274,021
12/31/2020 William J. Febbo
CHIEF EXECUTIVE OFFICER; Director
21,186   Derivative/Non-derivative trans. at $0 per share. 0
12/31/2020 Gus D. Halas
Director
802   Award at $0 per share. 0
12/31/2020 Ellen O'Connor Vos
Director
802   Award at $0 per share. 0
12/31/2020 James D. Lang
Director
802   Award at $0 per share. 0
12/31/2020 Patrick D. Spangler
Director
802   Award at $0 per share. 0
12/31/2020 Gregory D. Wasson
Director
802   Award at $0 per share. 0
11/12/2020 Douglas Paul Baker
CHIEF FINANCIAL OFFICER
15,000   Derivative/Non-derivative trans. at $2.46 per share. 36,900
11/11/2020 Douglas Paul Baker
CHIEF FINANCIAL OFFICER
15,000   Disposition at $24.05 per share. 360,750
09/30/2020 William J. Febbo
CHIEF EXECUTIVE OFFICER; Director
21,186   Derivative/Non-derivative trans. at $0 per share. 0
09/30/2020 Gus D. Halas
Director
1,183   Award at $0 per share. 0
09/30/2020 Ellen O'Connor Vos
Director
1,183   Award at $0 per share. 0
09/30/2020 James D. Lang
Director
1,183   Award at $0 per share. 0
09/30/2020 Patrick D. Spangler
Director
1,183   Award at $0 per share. 0
09/30/2020 Gregory D. Wasson
Director
1,183   Award at $0 per share. 0
/news/latest/company/us/oprx

MarketWatch News on OPRX

  1. OptimizeRx stock price target raised to $75 from $60 at B. Riley

    9:42 a.m. Feb. 25, 2021

    - Tomi Kilgore

  2. How to Benefit From Tech’s Run, Without Big Tech Exposure

    2:20 p.m. Feb. 13, 2021

    - Barron's Online

/news/nonmarketwatch/company/us/oprx

Other News on OPRX

  1. OPTIMIZERX CORP (OPRX) Q1 2021 Earnings Call Transcript

    1:31 a.m. May 7, 2021

    - Motley Fool

  2. One Last Hurrah? The Stocks To Buy Now

    4:09 a.m. April 25, 2021

    - Seeking Alpha

  3. OptimizeRx Stock Is Just Getting Started

    5:57 a.m. April 20, 2021

    - Seeking Alpha

  4. Veeva: Great Company But Not The Time To Buy

    7:19 a.m. April 5, 2021

    - Seeking Alpha

  5. 2 Biotech Stocks That Could Be Millionaire Makers

    6:15 a.m. April 4, 2021

    - Motley Fool

  6. Company News for Mar 17, 2021

    8:52 a.m. March 17, 2021

    - Zacks.com

  7. SVRA, ZYNE, CANF and CLSK among midday movers

    12:41 p.m. March 16, 2021

    - Seeking Alpha

  8. 10-K: OPTIMIZERX CORP

    5:19 p.m. March 8, 2021

    - Edgar Online - (EDG = 10Q, 10K)

  9. OptimizeRx priced its stock offering

    10:20 a.m. Feb. 9, 2021

    - Seeking Alpha

  10. OptimizeRx announces proposed public offering

    5:23 p.m. Feb. 8, 2021

    - Seeking Alpha

  11. OptimizeRx's (OPRX) Shares March Higher, Can It Continue?

    12:17 p.m. Feb. 4, 2021

    - Zacks.com

  12. OptimizeRx trades high on positive Q4 guidance

    10:05 a.m. Jan. 25, 2021

    - Seeking Alpha

  13. Loading more headlines...

At a Glance

OptimizeRx Corp.

400 Water Street

Suite 200

Rochester, Michigan 48307

Phone

1 2486516568

Industry

Computer Services

Sector

Business/Consumer Services

Fiscal Year-end

12/2021

Revenue

$43.31M

Net Income

$-2.21M

2020 Sales Growth

76.1%

Employees

57.00

/news/pressrelease/company/us/oprx

Press Releases on OPRX

  1. OptimizeRx Corp. to Host Earnings Call

    2:47 p.m. May 6, 2021

    - ACCESSWIRE

  2. OptimizeRx Expands Omni-channel Platform Reach at Point-Of-Care

    7:51 a.m. April 27, 2021

    - GlobeNewswire

  3. OptimizeRx Corp. to Host Earnings Call

    3:31 p.m. Feb. 24, 2021

    - ACCESSWIRE

  4. OptimizeRx's Angelo Campano Named to MM+M 40 Under 40 List

    8:31 a.m. Feb. 23, 2021

    - GlobeNewswire

  5. OptimizeRx Announces Pricing of Public Offering of Common Stock

    10:10 a.m. Feb. 9, 2021

    - GlobeNewswire

  6. OptimizeRx Announces Proposed Public Offering of Common Stock

    5:18 p.m. Feb. 8, 2021

    - GlobeNewswire

  7. Loading more headlines...
Trending Tickers
  • /quotes/zigman/17636479/composite VUZI+15.60%
  • /quotes/zigman/237947/composite JCP-5.83%
  • /quotes/zigman/59392505/composite NUGT-2.93%
  • /quotes/zigman/59386294/composite JNUG-5.94%
  • /quotes/zigman/65801738/composite TLT+1.11%
X
Powered by StockTwits
Link to MarketWatch's Slice.